ArticleCancer science2014

Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.

Jie Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.